✦ LIBER ✦

34 POSTER A phase II study of the combination of bevacizumab and erlotinib in patients with patients with unresectable hepatocellular carcinoma

✍ Scribed by M. Thomas; M. Lwasaki; K. Higginbotham; R. Lozano; K. Glover; J. Abbruzzese

Book ID: 118623663
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 365 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)70040-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of erlotinib in patients w

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

✍ Melanie B. Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Th 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

## Abstract ## BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proporti

Phase II study of thalidomide in patient

Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma

✍ Albert Y. Lin; Nathalie Brophy; George A. Fisher; Sam So; Christopher Biggs; Tor 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

A Phase 1 dose-finding and pharmacodynam

A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma

✍ Choo, S.P.; Chowbay, B.; Ng, Q.S.; Thng, C.H.; Lim, Cindy; Hartono, S.; Koh, T.S 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 642 KB

Phase II study of bevacizumab and erloti

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

✍ Thomas Yau, Hilda Wong, Pierre Chan, T. J. Yao, R. Pang, T. T. Cheung, S. T. Fan 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 156 KB

AOSOP3 Combination of bevacizumab and er

AOSOP3 Combination of bevacizumab and erlotinib in the treatment of patients with advanced hepatocellular carcinoma with sorafenib-refractory disease: Results of a pilot phase II study

✍ T. Yau; H. Wong; P. Chan; T.J. Yao; T.T. Cheung; S.T. Fan; R.T. Poon 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Phase 2 study of bevacizumab plus erloti

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

✍ Philip A. Philip; Michelle R. Mahoney; Kyle D. Holen; Donald W. Northfelt; Henry 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 825 KB